Nuclear Medicine Training: Skills and Competencies Required for Practice in the 21st Century

Overview

Journal World J Nucl Med

Publisher Thieme

Specialty Nuclear Medicine

Date 2023 May 24

PMID 37223624

Authors

Ismaheel O Lawal

Affiliations

Soon will be listed here.

References

Bodei L, Chiti A, Modlin I, Scott A, Schoder H . The Path to the Future: Education of Nuclear Medicine Therapeutic Specialists as Responsible Physicians. J Nucl Med. 2019; 60(12):1663-1664. DOI: 10.2967/jnumed.119.232454. View

Parker C, Nilsson S, Heinrich D, Helle S, OSullivan J, Fossa S . Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369(3):213-23. DOI: 10.1056/NEJMoa1213755. View

Muylle K, Maffioli L . Nuclear Medicine Training in Europe: "All for One, One for All". J Nucl Med. 2017; 58(12):1904-1905. DOI: 10.2967/jnumed.117.201012. View

Sartor O, de Bono J, Chi K, Fizazi K, Herrmann K, Rahbar K . Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021; 385(12):1091-1103. PMC: 8446332. DOI: 10.1056/NEJMoa2107322. View

Neilly B, Dizdarevic S, Prvulovich L, Buscombe J, Lewington V . Nuclear medicine training and practice in the UK. Eur J Nucl Med Mol Imaging. 2015; 43(4):800-3. DOI: 10.1007/s00259-015-3255-7. View

Segall G, Grady E, Fair J, Ghesani M, Gordon L . Nuclear Medicine Training in the United States. J Nucl Med. 2017; 58(11):1733-1734. DOI: 10.2967/jnumed.117.200857. View

Lee S, Emmett L, Pattison D, Hofman M, Bailey D, Latter M . The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective. J Nucl Med. 2022; 63(6):819-822. DOI: 10.2967/jnumed.122.263996. View

Vaz S, Oliveira F, Herrmann K, Veit-Haibach P . Nuclear medicine and molecular imaging advances in the 21st century. Br J Radiol. 2020; 93(1110):20200095. PMC: 10993229. DOI: 10.1259/bjr.20200095. View

Velleman T, Kwee T, Dierckx R, Ongena Y, Noordzij W . The integrated nuclear medicine and radiology residency program in the Netherlands: strengths and potential areas for improvement according to nuclear medicine physicians and radiologists. Eur J Nucl Med Mol Imaging. 2022; 49(9):3016-3022. PMC: 9250465. DOI: 10.1007/s00259-022-05699-8. View

10.

Sathekge M, Bruchertseifer F, Vorster M, Morgenstern A, Lawal I . Global experience with PSMA-based alpha therapy in prostate cancer. Eur J Nucl Med Mol Imaging. 2021; 49(1):30-46. PMC: 8712297. DOI: 10.1007/s00259-021-05434-9. View

11.

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B . Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017; 376(2):125-135. PMC: 5895095. DOI: 10.1056/NEJMoa1607427. View

12.

Harolds J, Oates M, Guiberteau M, Ghesani M, Scanlon M, Iagaru A . New training pathways to dual certification in nuclear medicine and radiology. J Nucl Med. 2015; 56(6):17N-18N. View

13.

Johannes C, Ken H . The Disappearing Act of Nuclear Medicine in The Netherlands: Just a New Trick by the Great Harry Houdini?. J Nucl Med. 2021; 62(7):903-904. DOI: 10.2967/jnumed.121.262190. View

14.

Feuerecker B, Kratochwil C, Ahmadzadehfar H, Morgenstern A, Eiber M, Herrmann K . Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?. J Nucl Med. 2023; 64(5):685-692. DOI: 10.2967/jnumed.122.265353. View

15.

Farolfi A, Maria Lima G, Oyen W, Fanti S . Molecular Imaging and Theranostics-A Multidisciplinary Approach. Semin Nucl Med. 2019; 49(4):247-254. DOI: 10.1053/j.semnuclmed.2019.02.002. View